SALBUTAMOL SULFATE ( DrugBank: Salbutamol, Sulfate )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
111	先天性ミオパチー	2

111. 先天性ミオパチー

---

臨床試験数 : 11 /  薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 9

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05099107 (ClinicalTrials.gov)	October 25, 2021	15/10/2021	Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment	COMPIS- Congenital Myopathy Intervention Study. An Open-label, Cross Over, Randomised, Controlled Study Using Oral Salbutamol	Congenital Myopathy;Neuromuscular Diseases;Musculoskeletal Diseases;Nemaline Myopathy;Centronuclear Myopathy;Myosin Storage Myopathy	Drug: Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet;Drug: Salbutamol Only Product in Oral Dose Form	Vastra Gotaland Region	NULL	Enrolling by invitation	6 Years	30 Years	All	20	N/A	Sweden
2	EUCTR2019-001147-51-SE (EUCTR)	31/03/2020	27/09/2019	This is a treatment study for a muscle disorder known as congenital myopathy	Congenital myopathy intervention study - COMPIS	Congenital myopathy MedDRA version: 20.0;Level: PT;Classification code 10062547;Term: Congenital myopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Ventoline tablet 2mg INN or Proposed INN: SALBUTAMOL SULFATE Trade Name: Ventoline oral solution 0,4mg/ml INN or Proposed INN: SALBUTAMOL SULFATE	Västra götalandsregionen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Sweden